We are live on ! Find out more
SFAM

Springhill Fund Asset Management Portfolio holdings

AUM $20.9M
This Fund
S&P 500
This Quarter Est. Return
+8.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$20.9M
AUM Growth
-$40.7M
Cap. Flow
-$44.1M
Cap. Flow %
-211.32%
Top 10 Hldgs %
82.88%
Holding
30
New
13
Increased
2
Reduced
4
Closed
11

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$2.49M
2
JANX icon
Janux Therapeutics
JANX
+$1.84M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.79M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.72M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$1.29M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$6.21M
2
CYTK icon
Cytokinetics
CYTK
+$6.15M
3
AKRO
Akero Therapeutics
AKRO
+$5.56M
4
AZN icon
AstraZeneca
AZN
+$5.01M
5
VERA icon
Vera Therapeutics
VERA
+$4.63M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
26
Dyne Therapeutics
DYN
$4.68B
– –
-131,200
Closed -$3.09M
LEGN icon
27
Legend Biotech
LEGN
$3.65B
– –
-190,800
Closed -$6.21M
MRUS
28
DELISTED
Merus
MRUS
– –
-83,800
Closed -$3.52M
NRIX icon
29
Nurix Therapeutics
NRIX
$2.45B
– –
-160,500
Closed -$3.02M
VERA icon
30
Vera Therapeutics
VERA
$2.33B
– –
-109,400
Closed -$4.63M
1
2

Similar funds

FGN
Foundry Group Next Boulder, Colorado $21.1M AUM 35.51% 1-Year Est. Return
NTIMCH
New Thinking Investment Management Company (HK) Hong Kong $20.4M AUM 4.24% 1-Year Est. Return
CJL
Cyrus J. Lawrence New York $26.4M AUM 16.63% 1-Year Est. Return
GDCML
Galaxy Digital Capital Management LP New York $13.5M AUM
TC
Tarsadia Capital New York $5.64M AUM 15.7% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
MECA
Miller Equity Capital Advisors Irving, Texas $1.45M AUM 7.67% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Springhill Fund Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Springhill Fund Asset Management held 30 positions worth $20.9M, down 66% from $61.6M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Springhill Fund Asset Management withdrew a net $44.1M in Q1 2025, closing 11 positions and reducing 4 holdings. Its most notable exit was Legend Biotech, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Springhill Fund Asset Management opened a new position in Summit Therapeutics worth $2.4M.

  • Springhill Fund Asset Management's largest Q1 2025 buy was Summit Therapeutics: 124,307 shares worth $2.4M.
  • Springhill Fund Asset Management added most to Janux Therapeutics in Q1 2025, an estimated $1.84M increase.
  • Springhill Fund Asset Management's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $5.56M.
  • Springhill Fund Asset Management fully exited Legend Biotech in Q1 2025, selling an estimated $6.21M.
  • Springhill Fund Asset Management's ten largest holdings make up 83% of its $20.9M portfolio in Q1 2025.
  • Springhill Fund Asset Management opened 13 new positions and closed 11 in Q1 2025.
  • Springhill Fund Asset Management's portfolio value fell 66% quarter-over-quarter to $20.9M.

Based on Springhill Fund Asset Management's 13F filing for Q1 2025, filed 14 May 2025.